Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

A snapshot of Healx

PME talks to CSO Neil Thompson

- PMLiVE

BeiGene’s Brukinsa misses the mark in head-to-head Imbruvica trial

Failed to beat rival in rare white blood cell cancer

- PMLiVE

Signant Health appoints new chief compliance and security officer

Paul Drake joins with 30 years of experience

- PMLiVE

Wave’s challenge to Sarepta in Duchenne falls flat

Shares in the company down more than 50%

Roche Basel Switzerland

Roche to close $4.3bn Spark deal after FTC clearance

Comes on the heels of CMA green light

- PMLiVE

GSK files anti-BCMA drug for myeloma after second trial win

Important drug for GSK as it rebuilds R&D pipeline

- PMLiVE

Pharma’s race to digital

Federico Marchisio and Lorraine WaltersAs digital tools and technologies become ever more central to our lives they are increasingly being used to diagnose, treat and manage disease. Wearables are moving...

- PMLiVE

Entrepreneurial Winning Women

An executive education programme that supports women founders who have built profitable small companies

- PMLiVE

Gilead’s NASH hopes crushed as candidates fail again

Monotherapy and combination regimens produced disappointing results

- PMLiVE

Silos – a reflection on the second birthday of Porterhouse Insights

After another exciting year, Fabrice Allum, Managing Director at Porterhouse Insights, reflects on the benefits of cross-functional working for our pharmaceutical clients

Porterhouse Medical Group

- PMLiVE

FDA okays Amarin’s Vascepa for cardiovascular risk reduction

Drug is on course for blockbuster sales

- PMLiVE

UK’s CMA clears Roche’s $4.3bn takeover of Spark

Roche first announced deal in February

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links